Study on Two Oral Drugs (Cediranib and Olaparib) vs. One Drug (Olaparib) for Men with Advanced Prostate Cancer

Inclusion Criteria

• Men with advanced prostate cancer that has spread and is resistant to hormone therapy.
• Must have a confirmed diagnosis of prostate adenocarcinoma.
• Cancer must be documented as spreading through scans.
• Must have low testosterone levels due to medical or surgical treatment.
• Must show signs of cancer progression, such as rising PSA levels or new lesions on scans.
• Must have a tumor that can be safely biopsied.
• Must agree to provide tumor samples for research.
• Must have tried at least one previous treatment for advanced prostate cancer.
• Must have a life expectancy of at least 16 weeks.
• Must be able to swallow pills and have no digestive issues that affect absorption.
• Must have controlled blood pressure and thyroid function.
• Must agree to use effective birth control methods during the study and for three months after.
• Must be able to understand and sign a consent form.

Exclusion Criteria

• Recent chemotherapy, hormonal therapy (except certain hormone treatments), or other cancer treatments within the last 21 days.
• Recent changes in bone-strengthening treatments within 30 days.
• Untreated or symptomatic brain metastases.
• Previous treatment with similar drugs to cediranib or olaparib.
• Allergies to similar drugs.
• Use of certain medications that interact with the study drugs.
• Use of herbal products or remedies.
• Other invasive cancers within the last five years, except for certain skin or bladder cancers.
• Uncontrolled health conditions, such as heart problems or infections.
• Recent heart attack or stroke.
• History of certain heart conditions or surgeries.
• Recent major surgery or injury.
• History of bowel obstruction or bleeding.
• Dependency on IV nutrition.
• Blood disorders or active infections like HIV or hepatitis.
• Previous bone marrow transplant.
• Recent blood transfusions.
• Involvement in the study's planning or conduct.